[O2-01-05]: A placebo-controlled, double-blind trial of the selective AB-42 lowering agent, flurizan (MPC-7869, (R)-flurbiprofen) in patients with mild to moderate Alzheimer's disease

2005 ◽  
Vol 1 ◽  
pp. S95-S95 ◽  
Author(s):  
Gordon K. Wilcock ◽  
Sandra Black ◽  
Judy Haworth ◽  
Mark Laughlin ◽  
Suzanne Hendrix ◽  
...  
2009 ◽  
Vol 8 (1) ◽  
pp. 39-47 ◽  
Author(s):  
Alistair Burns ◽  
Roberto Bernabei ◽  
Roger Bullock ◽  
Alfonso J Cruz Jentoft ◽  
Lutz Frölich ◽  
...  

1990 ◽  
Vol 5 (6) ◽  
pp. 375-380 ◽  
Author(s):  
Michael A. Jenike ◽  
Marilyn Albert ◽  
Lee Baer ◽  
Jeanette Gunther ◽  
Christine Corvino

1981 ◽  
Vol 26 (6) ◽  
pp. 426-428 ◽  
Author(s):  
M. Fisman ◽  
H. Merskey ◽  
E. Helmes ◽  
J. Mccready ◽  
E.H. Colhoun ◽  
...  

Twenty-one patients with a diagnosis of Alzheimer's disease completed a double blind trial on lecithin 25 g daily. Equal improvement was noted in both the lecithin and placebo groups. Serum levels of lecithin measured 12-14 hours after its administration were also not increased compared with the levels in control patients. These findings of the ineffectiveness of lecithin inpatients with Alzheimer's disease are discussed in relation to the literature on this subject.


Sign in / Sign up

Export Citation Format

Share Document